中文名：SB 202190,p38 MAPK抑制劑

英文名：SB 202190

中文別名：4-(4-氟苯基)-2-(4-羥基苯基)-5-(4-吡啶基)-1H-咪唑

英文別名：152121-30-7|SB 202190|SB202190|SB-202190|FHPI|4-(4-Fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)-1H-imidazole|SB202190 (FHPI)|4-(4-(4-fluorophenyl)-5-(pyridin-4-yl)-1H-imidazol-2-yl)phenol|4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)imidazole|CH

純度：99%

貨號：S134307

包裝：25mg、100mg、5mg

Cas號：152121-30-7

存儲溫度：2-8°C儲存

產(chǎn)品介紹：

SB 202190 is a pyridinyl imidazole that inhibits the p38 pathway. The compound inhibits the isoforms p38α and p38β. SB 202190 has displayed the ability to activate CPP32-like caspases and induce apoptosis. Research demonstrates that when one residue of ERK2, a related p38 not inhibited by pyridinyl imidazoles, is changed it allows SB 202190 to bind. Studies have revealed that SB 202190 can improve leukemia cell growth by activating MEK/MAPK, as well as phosphorylate and activate MLK3.An inhibitor of the isoforms p38α and p38β.

查看阿拉丁官網(wǎng)此產(chǎn)品相關對應頁面：https://www.aladdin-e.com/zh_cn/S134307.html